Statement by FDA Commissioner Scott Gottlieb, M.D., and Biologics Center Director Peter Marks, M.D., Ph.D. on FDA ’ s continued efforts to stop stem cell clinics and manufacturers from marketing unapproved products that put patients at risk, while progressing the agency ’ s commitment to help advance legitimate stem cell product development under existing agency regulations

FDA statement on stem cell enforcement actions and agency activities to facilitate legitimate product development
Source: Food and Drug Administration - Category: American Health Source Type: news